基于血液基因组内型对脓毒症患者进行分类:一项前瞻性队列研究
该前瞻性观察性队列研究纳入荷兰两家ICU连续收治的脓毒症患者(发现队列306例、第一验证队列216例)及英国29家ICU社区获得性肺炎所致脓毒症患者(第二验证队列265例),对入组时血液样本进行全基因组基因表达谱分析,采用无监督共识聚类和机器学习方法。在发现队列中识别出Mars1-4四种分子内型,与28天死亡率相关(log-rank p=0.022);Mars1内型预后最差,28天死亡35/90(39%),HR vs 其他内型1.86(95%CI 1.21-2.86;p=0.0045)。140基因表达特征可在两个验证队列中可靠分层四种内型,仅Mars1在各队列中与28天死亡率 consistently 显著相关。作者认为检测脓毒症内型可能有助于个体化管理及试验筛选。
要点
- 发现队列中Mars1内型28天死亡35/90(39%),HR vs 其他内型1.86(95%CI 1.21-2.86;p=0.0045),为四种内型中预后最差。
- Mars2内型28天死亡23/105(22%),HR 0.64(95%CI 0.40-1.04;p=0.061);Mars3内型16/71(23%),HR 0.71(95%CI 0.41-1.22;p=0.19);Mars4内型13/40(33%),HR 1.13(95%CI 0.63-2.04;p=0.69)。
- 联合临床与内型模型的净重分类改善为0.33(95%CI 0.09-0.58;p=0.008),显著改善风险预测。
- 140基因表达特征在第一和第二验证队列中均能可靠地将脓毒症患者分层为四种内型。
- 仅Mars1内型在各队列中与28天死亡率 consistently 显著相关;BPGM和TAP2可可靠识别Mars1内型患者。
适用人群与场景
- 荷兰两家ICU于2011年1月1日至2012年7月20日连续收治的脓毒症患者(发现队列和第一验证队列)。
- 英国29家ICU收治的社区获得性肺炎所致脓毒症患者(第二验证队列)。
研究设计与关键结果
- 研究类型为前瞻性观察性队列研究;发现队列306例,第一验证队列216例,第二验证队列265例;荷兰两中心及英国29家ICU。
- 发现队列中识别出Mars1-4四种分子内型,与28天死亡率相关(log-rank p=0.022)。
- Mars1内型28天死亡35/90(39%),HR vs 其他内型1.86(95%CI 1.21-2.86;p=0.0045);Mars2内型23/105(22%),HR 0.64(95%CI 0.40-1.04;p=0.061);Mars3内型16/71(23%),HR 0.71(95%CI 0.41-1.22;p=0.19);Mars4内型13/40(33%),HR 1.13(95%CI 0.63-2.04;p=0.69)。
- 联合临床与内型模型的净重分类改善为0.33(95%CI 0.09-0.58;p=0.008)。
- 140基因表达特征在第一和第二验证队列中均能可靠分层四种内型;仅Mars1在各队列中与28天死亡率 consistently 显著相关;BPGM和TAP2可可靠识别Mars1内型患者。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,检测脓毒症内型可能有助于提供个体化管理并用于试验筛选。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Host responses during sepsis are highly heterogeneous, which hampers the identification of patients at high risk of mortality and their selection for targeted therapies. In this study, we aimed to identify biologically relevant molecular endotypes in patients with sepsis.
METHODS: This was a prospective observational cohort study that included consecutive patients admitted for sepsis to two intensive care units (ICUs) in the Netherlands between Jan 1, 2011, and July 20, 2012 (discovery and first validation cohorts) and patients admitted with sepsis due to community-acquired pneumonia to 29 ICUs in the UK (second validation cohort). We generated genome-wide blood gene expression profiles from admission samples and analysed them by unsupervised consensus clustering and machine learning. The primary objective of this study was to establish endotypes for patients with sepsis, and assess the association of these endotypes with clinical traits and survival outcomes. We also established candidate biomarkers for the endotypes to allow identification of patient endotypes in clinical practice.
FINDINGS: The discovery cohort had 306 patients, the first validation cohort had 216, and the second validation cohort had 265 patients. Four molecular endotypes for sepsis, designated Mars1-4, were identified in the discovery cohort, and were associated with 28-day mortality (log-rank p=0·022). In the discovery cohort, the worst outcome was found for patients classified as having a Mars1 endotype, and at 28 days, 35 (39%) of 90 people with a Mars1 endotype had died (hazard ratio [HR] vs all other endotypes 1·86 [95% CI 1·21-2·86]; p=0·0045), compared with 23 (22%) of 105 people with a Mars2 endotype (HR 0·64 [0·40-1·04]; p=0·061), 16 (23%) of 71 people with a Mars3 endotype (HR 0·71 [0·41-1·22]; p=0·19), and 13 (33%) of 40 patients with a Mars4 endotype (HR 1·13 [0·63-2·04]; p=0·69). Analysis of the net reclassification improvement using a combined clinical and endotype model significantly improved risk prediction to 0·33 (0·09-0·58; p=0·008). A 140-gene expression signature reliably stratified patients with sepsis to the four endotypes in both the first and second validation cohorts. Only Mars1 was consistently significantly associated with 28-day mortality across the cohorts. To facilitate possible clinical use, a biomarker was derived for each endotype; BPGM and TAP2 reliably identified patients with a Mars1 endotype.
INTERPRETATION: This study provides a method for the molecular classification of patients with sepsis to four different endotypes upon ICU admission. Detection of sepsis endotypes might assist in providing personalised patient management and in selection for trials.
FUNDING: Center for Translational Molecular Medicine, Netherlands.
参考来源
- Scicluna BP, van Vught LA, Zwinderman AH, et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med. 2017. PMID: 28864056. doi:10.1016/S2213-2600(17)30294-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。